Clearside Biomedical Appoints Dr. George Lasezkay as President and Chief Executive Officer
“I am excited about having the opportunity to continue working closely with the Clearside team and I am grateful to the
About George Lasezkay, Pharm.D., J.D.
Dr. Lasezkay has an accomplished history of success in the life sciences industry. For the past 15 years, he has served as an independent director on the boards of a number of domestic and foreign emerging biopharmaceutical companies, including serving as a director of Clearside since
Previously, Dr. Lasezkay served as Executive Vice President and General Counsel at
Dr. Lasezkay has played a critical role in developing corporate strategy and has been responsible for a wide variety of licensing, research and development collaboration and acquisition transactions involving new technologies, products and companies. He also has a multi-disciplinary background in private firm and in-house legal practice, hospital pharmacy practice, clinical pharmacokinetics consultation and clinical drug research.
Dr. Lasezkay earned his
About
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include statements regarding the potential of the suprachoroidal injection platform. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended
Investor and Media Contacts:
ir@clearsidebio.com
(678) 430-8206
Source:
Source: Clearside Biomedical, Inc.